Salix Pharmaceuticals (SLXP) 157.33 $SLXP
45.1% Return Seen to Date on SmarTrend Salix Pharmaceuticals Call (SLXP)
Comtex SmarTrend(R) - Wed Sep 03, 10:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 45.12% as of today's recent price of $158.28.
Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix
PR Newswire - Wed Sep 03, 8:15AM CDT
Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.
Salix Submits Response to XIFAXAN(R) 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
Business Wire - Tue Sep 02, 6:19AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company's supplemental New Drug Application (sNDA) for XIFAXAN(R) 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix's response, the FDA will have six months to issue a response.
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 44.2% (SLXP)
Comtex SmarTrend(R) - Wed Aug 27, 9:37AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 44.18% as of today's recent price of $157.25.
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
After Big Run, Does Chip Designer NXP Have More Left?
at Investor's Business Daily - Tue Aug 26, 4:27PM CDT
Stock Spotlight has been serving up plenty of strong performers in recent weeks -- not surprising, since the market is in a confirmed uptrend. If the stock market has shown us one thing in recent weeks, it's that breakouts from late-stage bases can...
Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma
PR Newswire - Tue Aug 26, 7:50AM CDT
On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at:
Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
S&P 500 Marks New High As Indexes Hold Gains
at Investor's Business Daily - Thu Aug 21, 3:30PM CDT
Major averages closed modestly higher Thursday after existing-home sales, weekly jobless claims and Philly Fed factory data came in above expectations. The Dow industrials led with a 0.4% gain, while the S&P 500 added 0.3% to a new high. The Nasdaq...
SALIX PHARMACEUTICALS
at Investor's Business Daily - Wed Aug 20, 5:56PM CDT
SALIX PHARMACEUTICALS (SLXP) fell 2.2% after Bloomberg reported that Allergan (AGN) takeover talks -- an effort to fend off Valeant's (VRX) hostile bid for Allergan -- are dormant. Salix closed down 2.3% after spiking 15.5% on Tue. on WSJ's report of...
Salix Pharmaceuticals Jumps on Takeover Rumours by Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:45PM CDT
Salix Pharmaceuticals (SLXP) shares surged 15.5% after The Wall Street Journal claimed that Allergan (AGN) has approached Salix to acquire it.
Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up
at Investor's Business Daily - Wed Aug 20, 12:11PM CDT
Stocks have turned mixed after lingering in mildly lower territory early on. Thanks to Home Depot (HD) and Boeing (BA), the Dow Jones industrial average rose 0.2%. The S&P 500 edged up 0.1% after falling 0.2%. Meanwhile, the Nasdaq was near the flat...
Salix announces termination of HSR Waiting Period for pending merger with Cosmo Pharmaceuticals SpA
M2 - Wed Aug 20, 10:36AM CDT
Pharmaceutical company Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Tuesday a notice of the early termination of the waiting period for US antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its merger with Cosmo Pharmaceuticals SpA (SIX:COPN).
Salix Pharmaceuticals Has Returned 46.4% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Aug 20, 9:11AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 46.40% as of today's recent price of $159.68.
Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 8:46AM CDT
Salix Pharmaceuticals (SLXP) was a big mover last session, as the company saw its shares rise nearly 16% on the day.
Aug. 20 Premarket Briefing: 10 Things You Should Know
at The Street - Wed Aug 20, 5:35AM CDT
U.S. stock futures are mixed; a report says Allergan approached Salix and at least one other company about a potential acquisition; Citigroup weighs sale of Japan unit.
Video: Allergan May Seek Salix Deal To Avoid Valeant
at Investor's Business Daily - Tue Aug 19, 6:06PM CDT
Allergan is looking at potential acquisitions to prevent a hostile takeover from Valeant Pharmaceuticals and reportedly has approached Salix Pharmaceuticals and at least one other firm about a takeover. A deal between Salix (SLXP) and Botox maker...
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Indexes Rally On Strong Housing Data, Retail Reports
at Investor's Business Daily - Tue Aug 19, 4:03PM CDT
Stocks rallied into the close Tuesday, boosting the major averages to moderate gains on bullish housing data and strong earnings reports from retailers, including Home Depot (HD) and TJX Cos. (TJX). The S&P 500 and Dow industrials each rose 0.5%,...
After Yesterday's Rally of 15.54% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 19, 3:39PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $138.17 to a high of $162.38. Yesterday, the shares gained 15.5%, which took the trading range above the 3-day high of $141.79 on volume of 6.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
45.1% Return Seen to Date on SmarTrend Salix Pharmaceuticals Call (SLXP)
Comtex SmarTrend(R) - Wed Sep 03, 10:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 45.12% as of today's recent price of $158.28.
Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix
PR Newswire - Wed Sep 03, 8:15AM CDT
Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.
Salix Submits Response to XIFAXAN(R) 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
Business Wire - Tue Sep 02, 6:19AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company's supplemental New Drug Application (sNDA) for XIFAXAN(R) 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix's response, the FDA will have six months to issue a response.
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 44.2% (SLXP)
Comtex SmarTrend(R) - Wed Aug 27, 9:37AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 44.18% as of today's recent price of $157.25.
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...
After Big Run, Does Chip Designer NXP Have More Left?
at Investor's Business Daily - Tue Aug 26, 4:27PM CDT
Stock Spotlight has been serving up plenty of strong performers in recent weeks -- not surprising, since the market is in a confirmed uptrend. If the stock market has shown us one thing in recent weeks, it's that breakouts from late-stage bases can...
Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma
PR Newswire - Tue Aug 26, 7:50AM CDT
On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at:
Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
S&P 500 Marks New High As Indexes Hold Gains
at Investor's Business Daily - Thu Aug 21, 3:30PM CDT
Major averages closed modestly higher Thursday after existing-home sales, weekly jobless claims and Philly Fed factory data came in above expectations. The Dow industrials led with a 0.4% gain, while the S&P 500 added 0.3% to a new high. The Nasdaq...
SALIX PHARMACEUTICALS
at Investor's Business Daily - Wed Aug 20, 5:56PM CDT
SALIX PHARMACEUTICALS (SLXP) fell 2.2% after Bloomberg reported that Allergan (AGN) takeover talks -- an effort to fend off Valeant's (VRX) hostile bid for Allergan -- are dormant. Salix closed down 2.3% after spiking 15.5% on Tue. on WSJ's report of...
Salix Pharmaceuticals Jumps on Takeover Rumours by Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:45PM CDT
Salix Pharmaceuticals (SLXP) shares surged 15.5% after The Wall Street Journal claimed that Allergan (AGN) has approached Salix to acquire it.
Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up
at Investor's Business Daily - Wed Aug 20, 12:11PM CDT
Stocks have turned mixed after lingering in mildly lower territory early on. Thanks to Home Depot (HD) and Boeing (BA), the Dow Jones industrial average rose 0.2%. The S&P 500 edged up 0.1% after falling 0.2%. Meanwhile, the Nasdaq was near the flat...
Salix announces termination of HSR Waiting Period for pending merger with Cosmo Pharmaceuticals SpA
M2 - Wed Aug 20, 10:36AM CDT
Pharmaceutical company Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Tuesday a notice of the early termination of the waiting period for US antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its merger with Cosmo Pharmaceuticals SpA (SIX:COPN).
Salix Pharmaceuticals Has Returned 46.4% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Aug 20, 9:11AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 46.40% as of today's recent price of $159.68.
Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 8:46AM CDT
Salix Pharmaceuticals (SLXP) was a big mover last session, as the company saw its shares rise nearly 16% on the day.
Aug. 20 Premarket Briefing: 10 Things You Should Know
at The Street - Wed Aug 20, 5:35AM CDT
U.S. stock futures are mixed; a report says Allergan approached Salix and at least one other company about a potential acquisition; Citigroup weighs sale of Japan unit.
Video: Allergan May Seek Salix Deal To Avoid Valeant
at Investor's Business Daily - Tue Aug 19, 6:06PM CDT
Allergan is looking at potential acquisitions to prevent a hostile takeover from Valeant Pharmaceuticals and reportedly has approached Salix Pharmaceuticals and at least one other firm about a takeover. A deal between Salix (SLXP) and Botox maker...
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Indexes Rally On Strong Housing Data, Retail Reports
at Investor's Business Daily - Tue Aug 19, 4:03PM CDT
Stocks rallied into the close Tuesday, boosting the major averages to moderate gains on bullish housing data and strong earnings reports from retailers, including Home Depot (HD) and TJX Cos. (TJX). The S&P 500 and Dow industrials each rose 0.5%,...
After Yesterday's Rally of 15.54% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 19, 3:39PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $138.17 to a high of $162.38. Yesterday, the shares gained 15.5%, which took the trading range above the 3-day high of $141.79 on volume of 6.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
